Diabetes Drug Mounjaro Found to Cut Heart Attack Risk by a Third for First Time

A new study published in The BMJ has found that patients taking the diabetes medication Mounjaro (tirzepatide) are 33% less likely to suffer a heart attack compared to those on another type 2 diabetes medication. This significant reduction in cardiovascular risk is being hailed as a major development in the treatment of cardiovascular disease.

The study involved nearly 53,000 people, making it one of the largest clinical trials ever conducted. Researchers collected extensive data, which raises questions about our current approach to managing chronic conditions. On the surface, Mounjaro appears to be reducing hospital admissions due to infections by about one per 48 patients and lowering mortality rates by one death per 122 patients.

However, these benefits come at a cost: increased reports of hair loss, a known side effect of GLP-1 agonist drugs like Mounjaro. The UK Medicines and Healthcare products Regulatory Agency has received over 900 reports of hair loss linked to Mounjaro since 2026 alone. This number underscores the need for more research into the long-term effects of these medications.

While Mounjaro and similar medications may offer short-term solutions for individual patients, they also raise fundamental questions about our approach to healthcare. Rather than relying on medication to treat symptoms, perhaps it’s time we started thinking more critically about the underlying causes of chronic conditions – including lifestyle factors, environmental influences, and social determinants.

The benefits of Mounjaro should not be taken at face value. They may offer short-term solutions for individual patients but also raise questions about our priorities in healthcare. As we move forward, it’s time to start asking tough questions: what exactly do we hope to achieve by medicating our way out of chronic conditions?